Xandex Investments LLP
VC Fund
Petaluma, United States
Xandex Investments LLP is a VC fund in Petaluma focused on Health Care and Biotechnology. Xandex Investments is a California Limited Liability Company, wholly owned by Xandex Inc. and is the venture capital arm of Xandex Inc. The LLC was formed in 2005 to hold passive venture capital investments made by Xandex Inc. in prior years. In 2007, the LLC began direct investments in seed, angel and early stage rounds in promising technology companies. In addition to funding, access to Xandex Inc.'s 30 years of design, manufacturing and business experience is offered to portfolio companies. We call it our "Head Start" advantage.
- Total investments:
- 13
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries Xandex Investments LLP invests in
Stages Xandex Investments LLP invests in
Countries Xandex Investments LLP invests in
Round sizes
Round size
- Seed
- $605k–$4M
- Series A
- $3.4M–$17M
- Venture - Series Unknown
- $900k–$4M
Investment Focus
Industry
- Health Care 5 (38%)
- Biotechnology 5 (38%)
- Medical 3 (23%)
- Agriculture 3 (23%)
- Food and Beverage 3 (23%)
Stage
- Series A 5 (38%)
- Seed 3 (23%)
- Venture - Series Unknown 3 (23%)
- Series B 1 (8%)
- Series D 1 (8%)
Country
- United States 12 (92%)
- Ireland 1 (8%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Saccharo is a biotech start-up in the immuno-oncology space that develops therapeutic products for the treatment of cancer and other novel diseases. Saccharo discovered a polysaccharide that surrounds human cancer cells. The Sacchario approach has a mechanism of action that allows drugs to have multiple killing effects, a predicted safety profile,a broad therapeutic window, and applications to many cancers. | Venture - Series Unknown / Jan 01, 2021 | ||
| Hyalex Orthopaedics is a Lexington, MA medical device company advancing new products that feature HYALEX™ materials technology, a polymer that is designed to mimic cartilage. Unlike other polymers, synthetic HYALEX material has the unique capability of maintaining low friction and low wear under the high loads encountered in human joints. HyalexOrthopaedics' products are in the development stage and have not been approved for use in humans by any regulatory agency. | $17M / Series A / Mar 28, 2019 | ||
| Front Range Biosciences brings modern agriculture to cannabis and hemp to improve reliability, efficiency, and safety for cultivators and consumers. They provide advanced agricultural science services to plant growers. | $10M / Series A / Oct 04, 2018 | ||
| PathogenDx has developed a microarray based test specifically designed for the cannabis, botanical, food and agricultural testing markets. Our technology allows test labs to conduct between 12- 48 tests in parallel, testing up to 20 pathogens per test in less than a days’ shift. This is done at a fraction of the cost of plate counts or RealtimePCR. Our Raw Sample technology allows laboratories to bypass almost 20 steps that Real-time PCR must perform for DNA extraction and purification. PathogenDx technology bypasses the need for purification, quantitation, and normalization increasing the speed and affordability of pathogen screening. This helps our customers reduce testing time by 12 hours on the front end, and avoid spending money on sample prep kits and additional instrumentation. | $3.4M / Series A / Jul 17, 2018 | ||
| Thrive Bioscience is commercializing a family of instruments and software that provide imaging, analytics, and automation to significantly improve cell culture and the analysis of live cells. Thrive’s instruments empower biologists to deliver consistent, reproducible results by leveraging microscopy, robotics, fluidics, and other fields, to captureimages and data and provide analysis, reports, guidance, documentation, and a database on the cells and on cell culture processes. | $7.2M / Series A / Dec 30, 2016 | ||
| An alternative to traditional snacks; healthy, organic Barnana, the Super Potassium Snack, is pioneering the use of the banana's naturally occurring nutritional content. Barnana has no additives, no preservatives and is naturally sweet. Barnana's banana snacks are grown in sustainable, organic farms in South America and are an exceptionalsource of potassium, fiber and have over 20 vitamins and minerals. Original, Chocolate, Coconut, and Peanut Butter Organic Banana Bites can be found at Whole Foods, Safeway, Sprouts, and other finer grocers nationwide. | $4M / Venture - Series Unknown / Sep 22, 2016 | ||
| Vet24seven, Inc. introduces Ask.Vet, the online community where veterinarians engage and interact with animal owners to provide trusted, expert advice, information, & resources that help them with the care, health, and well-being of their animals. Ask.Vet was designed as the ‘go-to’ destination for the two hundred million households withanimals around the world. Questions are routed to a licensed veterinarian who is trained to educate, direct, and refer the client to a veterinarian, veterinary hospital, or other service providers nearby for diagnosis, treatment, and care. Veterinarians, clinics, and product/service providers will pay a referral free to Ask.Vet for qualified leads. | $605K / Seed / Aug 18, 2015 | ||
| Wildflower Health focuses on its client's needs and integrates services into existing sustainability programs. Its team is passionate about harnessing user-centered design and technology to deliver products that drive smarter healthcare decisions. It was founded in 2012 and headquartered in San Francisco, California. | $5M / Series B / Jun 26, 2015 | ||
| Revolve Robotics develop the best solution to give doctors, family members, caregivers and students a simple, engaging remote presence anywhere in the world. Our solution is called Kubi which is a combination of videoconferencing software and a cloud-controlled robot that lets remote callers move the tablet as if turning their own head. Kubi iscurrently being used for homebound students, behavioral health, pediatrics, eldercare, and rural healthcare.Kubi simplifies telepresence and increases engagement at a very affordable price. Kubi allows remote students and healthcare professionals to instantly login and interact from anywhere using live videoconferencing and the cloud controlled robot. Kubi integrates into existing workflows with leading video services Vidyo and Zoom. | $1.3M / Seed / Apr 03, 2015 | ||
| Nima develops breakthrough consumer products that enable users to know what is in their food. Nima believes mealtime should be about the enjoyment of food and the company and not the worry about the potential repercussions of eating something unknown. Their first product is a portable device that allows people to test their food for gluten. | $4M / Seed / Sep 11, 2014 | ||
| See all 13 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Xandex Investments LLP invest in?
Xandex Investments LLP invests primarily in Health Care, Biotechnology and Medical startups, most often at Series A and Seed stage. Most of the 13 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What round sizes does Xandex Investments LLP invest in?
Xandex Investments LLP typically joins rounds of $605k–$4M at Seed, $3.4M–$17M at Series A and $900k–$4M at Venture - Series Unknown. These are whole funding-round sizes, not Xandex Investments LLP's own check, which is rarely disclosed: the 10th–90th percentile of the confirmed public funding rounds Xandex Investments LLP took part in.
When did Xandex Investments LLP last invest?
The most recent investment recorded for Xandex Investments LLP closed in Jan 2021. Shizune tracks 13 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Nov 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
